skinny.

Latest / Breastcancer.org Podcast

Experimental Elacestrant Seems Effective for Breast Cancer Resistant to Other Types of Hormonal Therapy

Doctors are looking for new treatment options for people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Dr. Virginia Kaklamani is part of the team investigating elacestrant, an oral medicine, to see if offers more benefits than Faslodex (chemical name: fulvestrant), which is the current standard of care.

Listen to the podcast to hear Dr. Kaklamani explain:

the type of medicine elacestrant is and how it works

why it’s important that elacestrant showed benefits for breast cancers with…

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.